Eli Lilly and Company

Eli Lilly and Company

LLY
Eli Lilly and CompanyUS flagNew York Stock Exchange
1,183.86
USD
+32.87
- -
1.11TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.7
17.66
18.06
19.28
18.99
20.91
23.31
25.65
29.69
30.04
37.94
50.19
72.84
89.12
Basic EPS, GAAP
4.19
2.15
2.18
2.49
-0.19
3.14
8.69
6.47
5.85
6.57
5.83
11.8
23.07
29.88
Free Cash Flow per Basic Share
4.16
2.6
1.21
3.41
3.28
2.44
3.64
4.67
5.65
4.84
-3.5
0.46
6.67
15.17
Dividend per Share
1.9
1.89
1.92
1.96
2.08
2.25
2.52
2.81
3.24
3.72
4.52
5.21
6.02
6.47
Book Value per Share
15.79
13.84
13.18
12.72
10.54
9.3
2.72
5.9
9.42
11.21
11.98
15.81
29.65
38
Tangible Book Value per Share
11.91
9.66
4.97
5.16
2.9
7
-8.03
-5.83
-2.73
-0.66
-1.19
2.51
15.77
7.76
Basic Weighted Avg Shares
1,117
1,111
1,105
1,101
1,052
1,028
958
957
954
950
899
898
895
894
Sales/Revenue/Turnover
23,113
19,616
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
79,666
Operating Margin (%)
24
16.97
18
17.31
20.03
26.92
25.94
28.36
26.99
29.01
30.26
37.83
45.56
49.72
Depreciation Expense
1,446
1,379
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,522
1,527
1,767
1,997
2,099
Net Income, GAAP
4,685
2,390
2,408
2,738
-204
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
26,711
Effective Tax Rate (%)
20.45
20.32
13.68
18.86
103.75
14.39
11.93
14.33
9.32
8.25
20.05
16.48
19.79
20.49
Profit Margin (%)
20.27
12.19
12.07
12.9
-1.02
15.04
37.27
25.24
19.71
21.88
15.36
23.51
31.67
33.53
Working Capital
4,188
2,187
4,344
4,115
4,666
8,662
1,934
4,980
3,400
896
-1,566
4,364
20,401
16,931
LT Debt
4,200
5,333
7,972
8,368
9,940
9,196
13,818
16,587
15,346
14,738
18,321
28,527
40,868
47,858
Total Equity
17,641
15,388
14,590
14,080
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
33,879
Return on Invested Capital (%)
19.52
10.88
12.97
12.59
-0.6
20.9
25.67
29.05
28.27
28.34
25.98
33.89
40.74
40.9
Return on Capital (%)
22.3
10.85
11.08
12.3
-0.86
14.79
44.21
32.16
24.31
24.69
17.84
26.76
35.3
36.53
Return on Common Equity (%)
28.92
14.49
16.09
19.16
-1.59
30.18
133.78
150.18
76.35
63.63
48.92
84.84
101.36
102.44

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,635
4,000
7,050
LT Borrowings
40,868
39,370
47,858
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
895
894
892
Market Capitalization
961,624
821,814
1,069,292

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55,629
54,835
64,672
Cash, Cash Equivalents & STI
7,268
5,282
8,950
Accounts Receivable, Net
17,760
18,429
20,083
Inventories
13,744
14,529
16,793
Total Current Liabilities
35,228
36,634
47,741
Payables & Accruals
22,761
22,576
27,234
ST Debt
1,635
4,000
7,050
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.64%
38.59%
85.92%
Free Cash Flow
127.74%
212.97%
1,340.58%
Net Income, GAAP
-146.26%
36.58%
94.9%
Sales/Revenue/Turnover
13.43%
22.49%
44.7%
Total Cash Common Dividend
9.88%
14.91%
15.04%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,768
11,303
11,439
13,533
45,043
2025
12,729
15,558
17,601
19,292
65,179
2026
19,799
22,974
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.49
3.3
1.08
4.91
11.8
2025
3.07
6.3
6.23
7.42
23.07
2026
8.28
7.96
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.3
1.3
1.3
1.3
5.21
2025
1.5
1.5
1.5
1.5
6.02
2026
1.73
1.73
- -
- -
- -

Company Description

CEO
David A. Ricks
Full Time Employees
50,000
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
Lilly Corporate Center Indianapolis IN United States of America 46285
IPO Date
Jun 1, 1972
Website
lilly.com
Business

Company News

  • AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

  • TRex Bio Files For IPO As Collaboration With Eli Lilly Deepens

  • FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes

  • US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes

  • China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

  • Could Retatrutide Be Worth $10 Billion to Eli Lilly?

  • Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

  • Breakfast News: A Warning Shot for Housing?

  • Novo wants to change how Wall Street owns its stock: why now

  • Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring

  • Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

  • Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

  • Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study

  • His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000

  • Ken Langone on Eli Lilly: Could be a $2,000 stock in the next 3-4 years

  • Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.

  • Eli Lilly's Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon

  • Financial Review: Inhibikase Therapeutics (NASDAQ:IKT) vs. Eli Lilly and Company (NYSE:LLY)

  • Eli Lilly (LLY) Increases Yet Falls Behind Market: What Investors Need to Know

  • Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020